ClinicalTrials.gg

TargetBeta

F3

coagulation factor III, tissue factor · also CD142, TF · CD molecules

6 programs in company-led studies act on F3, from 6 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
tisotumab vedotinrulePfizerphase 4112 running–NCIt
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 333 running–NCIt
Anti-TF Antibody-drug Conjugate MRG004AruleLepu Biopharmaphase 321 running–NCIt
SHR-4375Jiangsu HengRui Medicinephase 222 running–the company's pipeline
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004ruleSutro Biopharmaphase 111 running–NCIt
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.